Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Antimicrobial resistance poses a major threat to global health as the number of efficient antimicrobials decreases and the number of resistant pathogens rises. Our research group has been actively involved in the design of novel antimicrobial drugs. The blueprints of these compounds were azolic heterocycles, particularly thiazole. Starting with oxadiazolines, our research group explored, one by one, the other five-membered heterocycles, developing more or less potent compounds. An overview of this research activity conducted by our research group allowed us to observe an evolution in the methodology used (from inhibition zone diameters to minimal inhibitory concentrations and antibiofilm potential determination) correlated with the design of azole compounds based on results obtained from molecular modeling. The purpose of this review is to present the development of in-house azole compounds with antimicrobial activity, designed over the years by this research group from the departments of Pharmaceutical and Therapeutical Chemistry in Cluj-Napoca.

Details

Title
An Insight into Rational Drug Design: The Development of In-House Azole Compounds with Antimicrobial Activity
Author
Ungureanu, Daniel 1   VIAFID ORCID Logo  ; Oniga, Ovidiu 2 ; Moldovan, Cristina 2   VIAFID ORCID Logo  ; Ionuț, Ioana 2 ; Gabriel, Marc 2   VIAFID ORCID Logo  ; Stana, Anca 2   VIAFID ORCID Logo  ; Pele, Raluca 2   VIAFID ORCID Logo  ; Duma, Mihaela 3   VIAFID ORCID Logo  ; Tiperciuc, Brîndușa 2   VIAFID ORCID Logo 

 Department of Pharmaceutical Chemistry, “Iuliu Hațieganu” University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania; [email protected] (D.U.); [email protected] (O.O.); [email protected] (C.M.); [email protected] (I.I.); [email protected] (G.M.); [email protected] (A.S.); [email protected] (B.T.); “Prof. Dr. Ion Chiricuță” Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; Department of Clinical Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy, 12 Ion Creangă Street, 400010 Cluj-Napoca, Romania 
 Department of Pharmaceutical Chemistry, “Iuliu Hațieganu” University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania; [email protected] (D.U.); [email protected] (O.O.); [email protected] (C.M.); [email protected] (I.I.); [email protected] (G.M.); [email protected] (A.S.); [email protected] (B.T.) 
 State Veterinary Laboratory for Animal Health and Safety, 1 Piața Mărăști Street, 400609 Cluj-Napoca, Romania; [email protected] 
First page
763
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20796382
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3097796849
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.